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Abstract: The aim of this research was to investigate the effect of normal and high doses of enrofloxacin on basal electrocardiographic
(ECG) parameters including corrected QT (QTc) values along with biochemical and haematological findings in healthy rabbits. In total
21 New Zealand rabbits were used. The animals were randomly divided into three groups including 7 rabbits in each. The normal dose
(5 mg/kg) of enrofloxacin and a toxic dose (50 mg/kg) were given intravenously in group 1, and the normal dose was given for 6 weeks
in group 2. The last group was designated as a negative control (group 3). ECG, serum biochemistry parameters, and total antioxidant
capacity (TAC) and total oxidant status (TOS) were determined every week. At the end of the experiment, necropsy was performed
and histology was evaluated. Some oxidative parameters were measured in the heart tissue. No cardiotoxic effect was observed on
ECG, in biochemical or haematological findings, or macroscopic or histological findings in groups 2 and 3. The results indicated that
enrofloxacin is not harmful for the heart in clinically healthy rabbits at normal and toxic doses compared with the negative control group
in terms of ECG, biochemical or haematological findings, or macroscopic or histological findings.
Key words: Rabbit, enrofloxacin, ECG and QT prolongation, haematology, biochemistry

1. Introduction
Prolongation of the QT interval is commonly used as a
surrogate marker of torsades de pointes (TdP), which is a
known clinical risk factor for the development of severe,
life-threatening, ventricular arrhythmias (Abi-Gerges et
al., 2004). Noncardiovascular drug-induced prolongation
of the QT interval is often associated with the onset
of TdP (Haverkamp et al., 2000; De Ponti et al., 2001).
Fluoroquinolones are among the drugs of choice for the
treatment of common bacterial infections due to their
wide spectrum against respiratory, gastrointestinal, and
genitourinary pathogens (Elmas et al., 2006). QT interval
prolongation is also a class effect of fluoroquinolones but
there are great differences between the various members
of this group (Camm, 2005). Thus, there are significant
differences in the potency to prolong QT interval among
the fluoroquinolones and the risk of arrhythmia varies
between drugs and with co-risk factors (Frothingham,
2001; Owens and Ambrose, 2002). Because a QT
prolongation and potentially fatal ventricular arrhythmias
associated with quinolones such as grepafloxacin due
to several cases of sudden death and TdP have been
encountered retrospectively, enrofloxacin needs to be
* Correspondence: rdurgut@gmail.com

further investigated in detail. Therefore, the purpose of this
study was to investigate the effect of normal and high doses
of enrofloxacin on basal electrocardiographic parameters
including heart rate (HR), P, QRS, QT, and RR intervals
and corrected QT (QTc) values as well as biochemical and
haematological findings in healthy conscious rabbits.
2. Materials and methods
2.1. Approvals
This study was approved by the Institutional Laboratory
Animal Care and Use Committee of Mustafa Kemal
University (2011 - 01 - 09).
2.2. Chemicals
All chemicals were obtained from Sigma Chemical Co,
and solutions were prepared fresh daily from concentrated
stock solutions.
2.3. Animal preparation
After 1 week of quarantine and acclimatisation, a total of 21
healthy New Zealand rabbits of both sexes, 12–18 months
old, and of 2–4 kg body weight were used. The rabbits were
housed individually in stainless-steel wire mesh cages and
provided with food and water ad libitum. All rabbits were
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treated with sulfaquinoxaline to decrease the incidence of
coccidial infections. The animals were housed in a room
maintained at a temperature of 23 ± 3 °C and a relative
humidity of 50 ± 10% with artificial lighting from 0800 to
2000 and with 13–18 air changes per hour.
The rabbits were randomly divided into three equal
groups including 7 rabbits in each. In the first group, normal
(5 mg/kg) and toxic doses (50 mg/kg) of enrofloxacin
(10 times the normal dose) were given (group 1). In the
second group, the normal dose (5 mg/kg) of enrofloxacin
was given for 6 weeks (group 2). The last group received
no drug and was designated as a negative group (group 3).
In the first group, enrofloxacin was injected
intravenously via the auricular vein at the dose of 5.0 mg/
kg bw (Enrofloxacin HCl, Baytril, 10%, Bayer, Turkey) over
10 min. The animals were assessed by ECG, haematology,
and serum biochemical analysis at 5, 10, 15, 20, and 30
min after the end of the first infusion. Then infusion
continued to peracute toxic effect, enrofloxacin at a 10fold dose of 50 mg/kg was injected over 10 min, and each
parameter was re-evaluated at 5, 10, 15, 20, 30, 45, and
60 min after the end of the infusion to the same animals.
Serum enrofloxacin concentration and its metabolite
ciprofloxacin were measured by using a standard highperformance liquid chromatographic method. In the
second group, for chronic toxic effect, the normal dose (5
mg/kg) of enrofloxacin was given for 6 weeks. ECG of all
the conscious animals was recorded every week. Serum
LDH, AST, CK, and CK-MB isoenzyme activities, and cTnI
levels and TAC and TOS were determined in all animals at
the sampling time. A clinical examination was performed,
body weights were measured weekly, and food and water
consumption recorded in the second group. For all groups,
at the end of experiment, necropsy was performed and
gross findings and histology were evaluated.
2.4. Assessment of ECG recordings in the conscious
rabbit
ECG records were taken by direct writing
electrocardiograph (Nihon Kohden, Cardiofax Vet, Japan).
ECG was standardised at 1 mV = 20 mm, with a chart
speed of 50 mm/s with the filter off. Lead II was used for
the measurements of intervals/durations and amplitudes.
Leads I, III, aVR, aVL, and aVF were also checked for any
abnormalities. Corrected QT values (QTc) were calculated
by using Carlsson’s formula (Carlsson et al., 1993) [QTc =
QT– 0.175(RR – 300)].
2.5. Biochemical and haematological measurement
The activities of LDH, AST, CK, and CK-MB isoenzyme,
and cTnI levels were assayed colorimetrically, according
to the standard procedures using commercially available
diagnostic kits (DiaSys Diagnostic Systems, Holzheim,
Germany). Furthermore, haematological parameters were
determined using an automatic analyser (Abacus Junior
Vet Systems, Budapest, Hungary).
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2.6. Serum total antioxidant capacities, total oxidant
status, and oxidative stress index
Total antioxidant capacities and total oxidant status
capacities were determined colorimetrically (PowerWave
XS, BioTek Instrument, Bedfordshire, UK) using a
commercial kit (Rel Assay Diagnostic, Gaziantep, Turkey)
as previously described by Durgut et al. (2013). Serum TAC
was determined using a novel automated measurement
method developed elsewhere (Erel, 2004). The results are
expressed as µmol of Trolox equivalent/litre.
Total oxidant status levels were measured using
commercially available kits (Rel Assay Diagnostic,
Gaziantep, Turkey). The assay was calibrated with hydrogen
peroxide (H2O2), and the results were expressed in terms
of micromolar H2O2 equivalent per litre (µmol H2O2
equivalent/L) (Erel, 2005). The OSI was calculated as the
ratio of TOS to TAC to determine the extent of oxidative
stress (Erel, 2004, 2005). OSI values were calculated using
the following formula: OSI = [(TOS, μmol/L)/(TAC, mmol
Trolox equivalent/L) × 100] (Erel, 2005).
2.7. Measurement of serum drug concentration
A volume of 3 mL of blood was drawn from the auricular
vein to measure the serum drug concentration. The blood
samples were centrifuged at 1500 × g for 30 min at 4 °C. The
serum was stored at –80 °C until the drug concentration
was measured. Determinations of the enrofloxacin
concentration were performed using a standard highperformance liquid chromatographic method (Model LC6A with UV spectrophotometric detector model SPD-6A,
data processor model chromatopac CR-6A; Shimadzu
Corp, Analytical Instrument Plant, Kyoto, Japan), as
described by Devreese et al. (2014). Enrofloxacin was
extracted from plasma using dichloromethane and
analysed by reverse-phase chromatography. The mobile
phase was a mixture of buffer (pH 2.2) and acetonitrile
(80:20, v/v). Heptane sulfonic acid-Na (1.1 g/L) added as
the ion-pairing reagent. Ultraviolet absorbance measured
at 278 nm was used for detection, with the flow rate
maintained at 2 mL/min. The linearity of the method
was examined by linear regression analysis of calibration
curves in plasma from goats. The recovery of enrofloxacin
was >90%. The limit of quantification of enrofloxacin was
0.01 pg/mL.
2.8. Necropsy and histopathology
At scheduled termination, all rabbits were sacrificed by
exsanguination from the neck. Complete gross postmortem
examinations were performed on all terminated animals.
The heart was obtained from all rabbits. The tissues were
fixed with 10% neutral buffered formalin solution. The
tissues were routinely processed, embedded in paraffin,
and sectioned at 3–5 µm. The sections were stained with
haematoxylin–eosin stain for microscopic examination.
All organs and tissues taken from all animals in the control
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and highest dose groups were examined microscopically.
All gross lesions as defined by the study histologist were
also included in the examination.
2.9. Statistical analysis
The groups and different time changes were evaluated
by one-way analysis of variance (ANOVA) with repeated
measurement design. Two-way ANOVA with repeated
measurement between groups was done with Duncan’s
multiple comparison test, and Bonferroni’s multiple
comparison test was used for differences between weeks.
The results were presented as means ± SEM. A P value
<0.05 was regarded as statistically significant.
3. Results
3.1. Peracute enrofloxacin administration
Two discrete results emerged from the study. First,
no evidence of weakness and no adverse effects on
general health were observed in rabbits treated at the
recommended dosage regimes or in a 10 times higher
dose of 50 mg/kg of enrofloxacin in all groups. Second,
there was no significant difference in the QT interval and
QTc, and other ECG parameters with the normal dose
of 5 mg/kg, and the highest dose of 50 mg/kg in rabbits
during the experiment. The electrophysiological effects of
enrofloxacin are summarised in Tables 1A and 1B.
A number of issues were identified. No statistically
significant changes in heart rate were observed at any
of the dose levels in group 1 during the experimental
procedure, but there was a dose-related increase in
plasma concentrations of enrofloxacin. The results of this
investigation show that enrofloxacin at clinically relevant
dose of 5 mg/kg and in a 10 times higher dose of 50 mg/
kg should have no torsadogenic potential. One of the
more significant findings to emerge from this study is that
enrofloxacin in the conscious rabbits had no effect on QTc

and causes QT prolongation only when administered at
normal and higher doses injected intravenously (Tables
1A and 1B).
As shown in Table 2, MCHC count significantly
increased in group 1 when compared with that at 0, 30,
and 60 min, and MCV count was significantly decreased at
30 min and increased at 60 min. As shown in Table 3, CK
significantly was increased at 60 min compared with that
at 0 and 30 min.
No statistically significant changes in serum
biochemical findings (as can be seen in Table 3), or TAC,
TOS, or OSI were observed in group 1 (Table 4). As Table
5 shows, there was a significant difference (P < 0.05) in
the serum concentration of enrofloxacin and its metabolite
ciprofloxacin between the sampling times.
3.2. Subacute enrofloxacin administration
As shown in Table 6, the body weight gain (g) of rabbits
did not significantly change in group 2 during the
experimental period. Food consumption by the rabbits in
group 2 did not change, and water consumption decreased
during the experimental period (data not shown).
The experimental design showed that enrofloxacin
or its metabolite ciprofloxacin, when administered at the
recommended dose of 5 mg/kg once daily for 6 weeks in
group 2, did not cause a significant prolongation in the
QT interval (Tables 7 and 8). It appears that enrofloxacin,
at clinically relevant doses and in a 10 times higher
dose of 50 mg/kg, had no torsadogenic potential either.
No statistically significant changes were observed in
haematological findings or serum biochemistry, TAC,
TOS, or OSI during the experimental period in group 2
(as can be seen in Tables 9–11). No statistically significant
changes were observed in mean serum concentration of
enrofloxacin or its metabolite ciprofloxacin between the
sampling times either (Table 12).

Table 1A. Interval amplitudes and other electrocardiographic parameters measured over lead II after the normal-dose injection of
enrofloxacin in group 1.
Time
0 min

5 min

10 min

15 min

20 min

30 min

Heart rate (bpm)

251.4 ± 11.9

263.4 ± 15.6

259.71 ± 15.07

253.29 ± 14.13

237 ± 17.13

245.57 ± 13.45

QT interval (ms)

153.43 ± 11.57

170.29 ± 4.12

172.7 ± 9.12

174.29 ± 8.66

168 ± 6.32

164.43 ± 6.32

QTc interval (ms)

204.14 ± 6.47

208.43 ± 4.04

205 ± 9.64

214.71 ± 9.55

198.57 ± 4.63

198.71 ± 5.82

PR interval (ms)

79.57 ± 9.44

50.57 ± 14.29

71.43 ± 2.72

62.86 ± 3.90

55 ± 9.37

57.43 ± 10.56

P interval (ms)

68.57 ± 8.75

50.14 ± 10.16

59.43 ± 3.64

51.14 ± 3.97

41.86 ± 7.10

46.43 ± 8.81

P amp (mV)

0.04 ± 0.01

0.02 ± 0.01

0.04 ± 0.01

0.03 ± 0.01

0.03 ± 0.01

0.03 ± 0.01

QRS complex (ms)

46.57 ± 2.39

42.43 ± 2.05

49.86 ± 9.13

48.14 ± 5.56

42 ± 8

46.86 ± 3.33

There was no statistical significance in the same column (P > 0.05). Values are presented as mean ± SEM.
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Table 1B. Interval amplitudes and other electrocardiographic parameters after in a 10 times higher dose of 50 mg/kg over 10 min in
group 1.
Time
5 min

10 min

15 min

30 min

45 min

60 min

Heart rate (bpm)

254.14 ± 13.40

254.43 ± 20.43

216.86 ± 34.87

272.14 ± 9.50

246.86 ± 14.61

249.71 ± 16.86

QT interval (ms)

175.86 ± 17.43

175.86 ± 4.13

169.86 ± 4.01

172.86 ± 5.94

178.57 ± 10.74

169.43 ± 5.91

QTc interval (ms)

199.29 ± 4.98

214.71 ± 3.30

207 ± 4.03

211.14 ± 5.07

214.57 ± 8.81

205.57 ± 6.24

PR interval (ms)

55.14 ± 9.57

44.14 ± 16.07

60.43 ± 11.20

75.14 ± 8.46

66.86 ± 4.60

68.86 ± 2.80

P interval (ms)

44.71 ± 7.74

46.71 ± 12.80

59.29 ± 12.83

55.00 ± 3.57

56.43 ± 5.11

57.14 ± 3.78

P amp (mV)

0.03 ± 0.01

0.01 ± 0.01

0.03 ± 0.11

0.03 ± 0.01

0.03 ± 0.01

0.02 ± 0.01

QRS complex (ms)

43.57 ± 2.28

50.14 ± 2.23

49.14 ± 4.59

41.43 ± 1.51

50.86 ± 7.12

50 ± 7.34

There was no statistical significance in the same column (P > 0.05). Values are presented as means ± SEM.
Table 2. Haematological parameters in rabbits treated enrofloxacin in group 1.
0 min

30 min

60 min

Leukocytes (×10 /L)

8.78 ± 1.13

8.69 ± 0.98

8.25 ± 0.53

Erythrocytes (×10 /L)

5.49 ± 0.23

5.43 ± 0.27

5.13 ± 0.30

Haematocrit (%)

33.39 ± 3.06

31.91 ± 2.96

31.23 ± 3.43

MCV (fL)

58.14 ± 0.91

58 ± 0.54

62.29 ± 0.81*

RDW (%)

15.96 ± 0.46

16.60 ± 0.75

16.94 ± 0.88

9

12

MCH (pg)

20.46 ± 1.49

21.77 ± 1.67

22.16 ± 0.82*

MCHC (g/dL)

35.36 ± 0.34

35.44 ± 0.25

35.39 ± 0.23

Platelets (×109/L)

359.86 ± 79.78

368.57 ± 67.24

360.14 ± 26.25

Lymphocytes (×109/L)

2.86 ± 0.57

2.51 ± 0.55

3.40 ± 0.66

Monocytes (×10 /L)

0.54 ± 0.07

0.47 ± 0.07

0.86 ± 0.25

Granulocytes (×10 /L)

5.98 ± 0.99

4.64 ± 0.78

5.45 ± 0.76

Haemoglobin (g/dL)

10.69 ± 1.40

11.51 ± 0.97

11.17 ± 0.91

9

9

MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean
corpuscular haemoglobin concentration; RDW, red blood cell distribution width. Values are
presented as means ± SEM. *There was statistical significance in the same line (P < 0.05).
Table 3. Serum biochemical findings in rabbits treated with enrofloxacin in group 1.
Aspartate
Creatine
Creatine phosphokinaseaminotransferase (IU/L) phosphokinase (IU/L) MB (IU/L)

Lactate dehydrogenase Cardiac troponin I
(IU/L)
(ng/mL)

0 min

31.14 ± 8.65

487.14 ± 66.28

332.57 ± 94.94

64.43 ± 11.42

0±0

30 min

23.86 ± 6.99

478.71 ± 77.66

333.43 ± 95.78

68.57 ± 10.52

0.004 ± 0.003

60 min

36.57 ± 5.34

2149.3 ± 363.43*

489.56 ± 154.10

195.43 ± 60.18

0.041 ± 0.016

*There was statistical significance in the same column (P < 0.05). Values are presented as means ± SEM.
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Table 4. Serum TAC, TOS, and OSI in group 1.
TAS
(mmol Trolox equiv./L)

TOS
(µmol H2O2 equiv./L)

OSI (arbitrary unit)

0 min

0.13 ± 0.03

5.49 ± 1.05

7298.29 ± 3182.72

30 min

0.04 ± 0.02

6.25 ± 1.59

71,961.29 ± 24,024.4

60 min

0.09 ± 0.02

20.73 ± 14.61

57,652.86 ± 37,453.99

There was no statistical significance in the same column (P > 0.05). Values are presented as
means ± SEM. TAC: Total antioxidant capacity, TOS: Total oxidant status, OSI: Oxidative
stress index.
Table 5. Mean serum concentration of enrofloxacin and its metabolite ciprofloxacin in group 1.
0 min

30 min

60 min

Enrofloxacin (mg/L)

0.000 ± 0.000

3.57 ± 1.31

85.71 ± 9.53c

Ciprofloxacin (mg/L)

0.000 ± 0.000a

0.16 ± 0.03b

7.75 ± 1.96c

a

b

Statistically significant among minutes marked with different letters (P < 0.05); the same letters
show no significance. Values are presented as means ± SEM.
Table 6. Body weights comparison during the experimental period in group 2.
Week 0
Body weights

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

2275.7 ± 510.3 2462.8 ± 341.7 2602.7 ± 353.8 2652.1 ± 209.7 2632.8 ± 224.5 2638.8 ± 247.9 2605.7 ± 185.4

There was no statistical significance in the same line (P > 0.05). Values are presented as means ±SEM.
Table 7. Interval amplitudes and other electrocardiographic parameters after treatment with enrofloxacin during the experimental
period in group 2.
Weeks
Week 0

Week 1

Week 2

Week 3

Week 4

Week 5

Heart rate (bpm)

227.72 ± 11.53

251.43 ± 8.48

238.00 ± 16.81

246.57 ± 13.80

233.43 ± 16.19

262.71 ± 13.49

QT interval (ms)

167.00 ± 3.57

162.00 ± 5.91

176.28 ± 7.42

158.57 ± 6.39

176.57 ± 7.45

162.00 ± 3.49

QTc interval (ms)

202.00 ± 4.55

199.14 ± 6.45

210.43 ± 6.64

194.57 ± 7.24

210.57 ± 8.45

200.43 ± 4.26

PR interval (ms)

78.571 ± 6.64

77.14 ± 5.97

70.14 ± 4.04

86.86 ± 8.41

73.86 ± 5.51

76.85 ± 5.86

P interval (ms)

61.714 ± 4.18

64.00 ± 6.07

55.14 ± 4.31

75.00 ± 10.60

63.85 ± 5.16

63.14 ± 6.55

P amp (mV)

0.016 ± 0.07

0.027 ± 0.01

0.025 ± 0.01

0.026 ± 0.01

0.031 ± 0.01

0.021 ± 0.01

QRS complex (ms)

43.28 ± 4.20

43.71 ± 2.53

45.14 ± 2.06

48.74 ± 6.654

55.57 ± 7.86

42.14 ± 3.47

There was no statistical significance in the same line (P > 0.05). Values are presented as means ± SEM.

No histopathological changes were observed in the
treatment groups except for some minor abnormalities
including hyperaemia in some heart areas when compared
to the negative control group (Figure 1A–1C).

4. Discussion
Fluoroquinolones are widely used and well tolerated
antibacterial agents for veterinary medicine. In our review
of the literature, no data were found on the association
between enrofloxacin and QT prolongation and TdP in
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Table 8. Interval amplitudes and other electrocardiographic parameters at the end of week 6 after treatment with enrofloxacin during
the experimental period in group 2.
Week 6
0 min

5 min

10 min

15 min

20 min

30 min

Heart rate (bpm)

240.86 ± 15.59

246.71 ± 11.87

245.57 ± 13.96

237.57 ± 15.68

225.00 ± 11.87

221.00 ± 16.58f

QT interval (ms)

172.43 ± 5.17a

184.57 ± 7.19a

172.14 ± 4.64a

176.57 ± 7.18a

172.43 ± 4.34a

170.29 ± 5.88a

QTc interval (ms)

207.57 ± 4.18

220.71 ± 7.77

202.86 ± 3.99

210.71 ± 7.41

204.57 ± 2.17

201.00 ± 3.22a

PR interval (ms)

96.29 ± 12.90a

81.14 ± 5.79a

71.29 ± 4.60a

82.86 ± 5.46a

75.29 ± 5.58a

80.86 ± 6.26a

P interval (ms)

85.43 ± 13.46

71.71 ± 6.76

59.14 ± 5.19

71.14 ± 6.01

64.86 ± 5.97

70.14 ± 6.89a

P amp (mV)

0.018 ± 0.01a

0.03 ± 0.01a

0.02 ± 0.01a

0.03 ± 0.01a

0.02 ± 0.01a

0.03 ± 0.01a

QRS complex (ms)

49.14 ± 1.91

61.29 ± 10.52

a

a

a

a

b

a

a

c

a

a

a

49.00 ± 3.38

a

d

a

a

54.86 ± 8.39

a

e

a

a

51.00 ± 2.18

a

46.86 ± 1.41a

Statistically significant among minutes marked with different letters (P < 0.05); the same letters show no significance. Values are
presented as means ± SEM.

Table 9. Haematological findings in rabbits treated with enrofloxacin during the experimental period in group 2.
Week 0

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Leukocytes (×109/L) 8.79 ± 1.1a

8.68 ± 0.9a

8.15 ± 0.5a

7.41 ± 0.5a

8.43 ± 0.7a

9.15 ± 0.6a

8.91 ± 0.9a

Erythrocytes
(×1012/L)

5.66 ± 0.2a

5.28 ± 0.2a

5.13 ± 0.2a

5.26 ± 0.3a

5.52 ± 0.2a

5.71 ± 0.2a

5.64 ± 0.3a

Haematocrit (%)

33.49 ± 1.3a

32.32 ± 1.1b

31.56 ± 1.3c

32.56 ± 1.6d

33.31 ± 1.4e

34.20 ± 1.0f

33.54 ± 1.4g

MCV (fL)

59.00 ± 1.3a

61.28 ± 1.2a

61.71 ± 0.8a

61.85 ± 1.0a

60.43 ± 0.8a

59.85 ± 0.7a

59.71 ± 1.0a

RDW (%)

16.16 ± 0.5a

16.78 ± 0.7a

16.70 ± 0.8a

16.48 ± 0.6a

15.44 ± 0.4a

14.97 ± 0.3a

15.08 ± 0.3a

MCH (pg)

20.80 ± 0.5a

22.03 ± 0.4a

21.81 ± 0.3a

21.75 ± 0.3a

22.03 ± 0.2a

21.27 ± 0.2a

21.55 ± 0.2a

MCHC (g/dL)

35.200 ± 0.3a

35.94 ± 0.3a

35.37 ± 0.2a

35.15 ± 0.2a

36.50 ± 0.3a

35.50 ± 0.3a

36.05 ± 0.5a

Platelets (×109/L)

371.57 ± 35a

377.28 ± 37a 403.00 ± 28a

490.28 ± 46a

399.43 ± 9.0a 315.14 ± 44a

305.28 ± 36.72a

Lymphocytes
(×109/L)

30.61 ± 6.55a

3.22 ± 0.82a

3.26 ± 0.65a

2.52 ± 0.60a

2.94 ± 0.7a

4.15 ± 0.91a

2.29 ± 0.60a

Monocytes (×109/L)

7.23 ± 1.09a

0.46 ± 0.09a

0.49 ± 0.14a

0.33 ± 0.03a

0.43 ± 0.1a

0.48 ± 0.08a

0.35 ± 0.06a

Granulocytes
(×109/L)

62.15 ± 6.28a

4.99 ± 0.46a

3.94 0.35a

4.56 ± 0.87a

5.05 ± 0.6a

4.50 ± 0.78a

4.67 ± 1.05a

Haemoglobin (g/dL) 11.81 ± 0.55a

11.61 ± 0.38a 11.13 ± 0.46a 11.45 ± 0.62a

12.16 ± 0.55a 12.14 ± 0.35a

12.18 ± 0.63a

Statistically significant among minutes marked with different letters (P < 0.05); the same letters show no significance. Values are
presented as means ± SEM.

clinically healthy rabbits. Therefore, the aim of this study
was to assess the importance of enrofloxacin using the
in vivo clinically healthy rabbit model with the normal
dose and in a 10 times higher dose injection with various
electrocardiographic parameters including RR, PQ, and
QT intervals; QRS duration; QT/QTc prolongation; or
TdP. Some authors speculated that increases in heart rate
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(HR), with accompanying decreases in QT intervals, could
be masking an inherent increase in QT interval, identified
with numerous drugs (Haverkamp et al., 2000; De Ponti
et al., 2001; Redfern et al., 2003; Kijtawornrat et al., 2006;
Ozkanlar et al., 2014). The reason for this was that a
correction formula that adequately corrected QT intervals
was used in the current study.
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Table 10. Serum biochemical findings in in rabbits treated with enrofloxacin during the experimental period in group 2
Aspartate
aminotransferase
(IU/L)

Creatine
phosphokinase
(IU/L)

Creatine
phosphokinase-MB
(IU/L)

Lactate dehydrogenase
(IU/L)

Cardiac troponin I
(ng/mL)

Week 0

31.71 ± 4.71

652.71 ± 212

551.86 ± 224

167.85 ± 57

0.039 ± 0.034

Week 1

32.85 ± 4.23

2867.85 ± 715

928.28 ± 457

194 ± 66

0.01 ± 0.006

Week 2

61.14 ± 28.02

1990.57 ± 442

429.14 ± 122

128 ± 18

0.003 ± 0.002

Week 3

41.86 ± 8.33

2865.28 ± 314

410.71 ± 116

157.71 ± 21

0.011 ± 0.007

Week 4

85.72 ± 23.56

3316.57 ± 469

350.71 ± 65

123.43 ± 14

0.006 ± 0.002

Week 5

196.57 ± 70.57

4700.28 ± 221

300 ± 27

254.28 ± 57

0.014 ± 0.005

Week 6

200.14 ± 70.64

3410.57 ± 625

320.43 ± 31

177.86 ± 37.16

0.007 ± 0.003

There was no statistical significance in the same line (P > 0.05). Values are presented as means ± SEM.
Table 11. Serum TAC, TOS, and OSI during the experimental period in group 2.
TAS
(mmol Trolox equiv./L)

TOS
(µmol H2O2 equiv./L)

OSI
(arbitrary unit)

Week 0

0.196 ± 0.04

20.363 ± 9.899

8732.86 ± 2089

Week 1

0.036 ± 0.013

6.008 ± 0.758

91,978.57 ± 4864

Week 2

0.005 ± 0.001

10.178 ± 5.281

266,430.4 ± 1165

Week 3

0.085 ± 0.039

5.790 ± 0.572

75,142.57 ± 6106

Week 4

0.080 ± 0.038

6.438 ± 0.526

103,966.1 ± 6377

Week 5

0.065 ± 0.038

7.329 ± 1.049

58,177.43 ± 1966

Week 6

0.083 ± 0.021

11.256 ± 1.550

42,212.14 ± 1874

There was no statistical significance in the same column (P > 0.05). Values are presented as
means ± SEM. TAC: Total antioxidant capacity, TOS: Total antioxidant status, OSI: Oxidative
stress index.
Table 12. Mean serum concentration of enrofloxacin and its metabolite ciprofloxacin during the experimental period in group 2.
Week 0

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Enrofloxacin (mg/L)

0±0

0±0

0±0

1.52 ± 0.14

0±0

0.98 ± 0.16

0±0

Ciprofloxacin (mg/L)

0±0

0±0

0±0

0.55 ± 0.22

0±0

0.11 ± 0.01

0±0

There was no statistical significance in the same line (P > 0.05). Values are presented as means ± SEM.

Drug-induced QT prolongation is relatively common
in clinical practice (De Ponti et al., 2001; Redfern et al.,
2003; Ozkanlar et al., 2005b). It has been reported that
sparfloxacin and grepafloxacin can prolong the QT
interval to cause lethal ventricular arrhythmias (Bertino
and Fish, 2000; Frothingham, 2001; Owens, 2001).
Therefore, this finding has important implications for
developing a therapeutic strategy. To date, there has been
no scientific research on enrofloxacin associated effects on
the rabbit’s heart. Rabbits may be dosed with 2.5–5 mg/

kg bw per day for 3–5 days by oral administration or by
intramuscular injection (Elmas et al., 2006). In the present
study, the normal dose of 5 mg/kg and the higher dose of
50 mg/kg were used in rabbits peracutely to investigate the
relationship between serum concentration (the normaldose and the higher-dose injection of enrofloxacin). In
the current experimental period of peracute (group 1)
and subacute application (Group 2), no QT prolongation,
recurrent syncope, or sudden cardiac death secondary
to atypical polymorphic ventricular tachycardia were
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Figure 1. Histological examination of rabbit heart in the negative control (A) shows normal morphology. Histological examination
of rabbit heart in group 1 (B) and group 2 (C) shows normal morphology except for some minor abnormalities including
hyperaemia in some areas (H&E, 400×).

observed. In the current study, no evidence of abnormal
ECG parameters was detected including RR, PQ, and QT
intervals; QRS duration and QTc; and heart rate at normal
and even a 10 times higher dose. A possible explanation
for these results may be that heart tissue of the rabbit may
be affected by even higher doses than those used in this
study.
TdP is very important in terms of developing effective
preclinical testing strategies and interpreting the data
accurately (Frothingham, 2001; Redfern et al., 2003).
Nevertheless, there was a significant difference (P < 0.05) in
the serum concentration of enrofloxacin and its metabolite
ciprofloxacin (a major metabolite of enrofloxacin) at
sampling intervals (as can be seen in Tables 5 and 12).
In contrast to earlier findings, however, no evidence of
QT/QTc prolongation or potentially fatal ventricular
arrhythmias associated with quinolones (Bertino and
Fish, 2000; Frothingham, 2001; Owens, 2001) was
detected in the current study. Hence, the data presented
here demonstrate that enrofloxacin had no torsadogenic
potential in rabbits at 5 mg/kg or higher dose of 50 mg/
kg. It is possible, therefore, that this would create a more
clinically relevant situation.
The plasma AST, LDH, and CK enzyme activities are
important measures of both early and late phases of cardiac
injury especially during clinical follow up (Saad et al.,
2001). In the present study, the activities of all these three
enzymes in plasma did not increase. They are not specific
for myocardial injury individually; however, evaluation of
these enzymes together may be an indicator of myocardial
injury. Serum cTnI and CK are the preferred markers for
the detection of minor ischemic cardiac injury (Apple
et al., 1997). By treating the rabbits with enrofloxacin,
AST, LDH, and CK enzyme activities and cTnI did not
significantly change. This suggests that enrofloxacin may
not have adverse effect on enzyme activities.
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Oxidative stress is generally described as an imbalance
between oxidant and antioxidant levels (Lykkesfeldt and
Svendsen, 2007). Nitric oxide (NO), essential for the proper
functioning of the cardiovascular system, is derived from
L-arginine by NO synthase (NOS) in endothelial cells.
NO synthase inhibition produces various cardiovascular
abnormalities and ventricular contractile dysfunction
(Loscalzo and Welch, 1995; Dickinson and Forman, 2002).
Although no previous report has investigated TAS, TOS,
and OSI as biomarkers of oxidative stress and antioxidant
defence related to treating the rabbits with enrofloxacin,
a possible explanation for this might be that free oxidant
radicals are not produced.
The histopathology of the heart in the treatment groups
did not show any remarkable changes, which was similar
to the negative control when stained with haematoxylin
and eosin and assessed using light microscopy. It can thus
be suggested that peracute and subacute enrofloxacin
application may have not adverse effects on myocardial
tissue.
The first major finding is that enrofloxacin, at clinically
relevant dose of 5 mg/kg and even excessive dosing (10
times higher dose of 50 mg/kg), has no electrophysiological
abnormalities particularly QT prolongation or torsadogenic
effect. It was also shown that administration of a daily
single dose of enrofloxacin intravenously was a safe
application protocol. This finding might be of use for safe
administration of enrofloxacin to animals and especially to
rabbits during infectious disease. However, more clinical
studies are needed to identify possible combinations of
medications that have a potential for a proarrhythmic effect.
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